IL33 and Alzheimer disease: Notably, drugs targeting IL-4, IL-13, and IL-33, including dupilumab, and JAK inhibitors like baricitinib, abrocitinib, and upadacitinib have been approved or are pending approval in certain regions for moderate to severe AD.